Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection. The Alter Study. Nordic HIV Therapy Group

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Molecular imaging in Libman-Sacks endocarditis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mycobacterium bovis meningitis in young Nigerian-born male

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Undetectable hepatitis C virus RNA during syphilis infection in two HIV/HCV-co-infected patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Pneumocystis jirovecii pneumonia in patients with end-stage renal disease: a comparison with the general population

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Antibacterial use in the Faroe Islands, Iceland, and Denmark 1999-2011

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. General health checks in adults for reducing morbidity and mortality from disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias

    Research output: Contribution to journalReviewResearchpeer-review

  3. Challenges of independent assessment of potential harms of HPV vaccines

    Research output: Contribution to journalJournal articleResearchpeer-review

  • J Gerstoft
  • H Melander
  • J N Bruun
  • C Pedersen
  • Peter C. Gøtzsche
  • O Berglund
  • L Mathiesen
  • P Skinhłj
  • S R Norrby
View graph of relations
The efficacy and safety of an alternating regime with zidovudine and didanosine versus treatment with either drug alone were investigated in a randomized, open, controlled trial, 552 patients with advanced HIV infection, 47% of whom had received prior treatment with zidovudine, were enrolled. The patients were randomly assigned to zidovudine 600 mg/day, didanosine 400 mg/day or 4-week alternations with the 2 drugs in the same dose. The study had a median length of follow-up of 88 weeks. In the overall analyses, time to death (p = 0.48) and time to death or new AIDA event (0.80) were equally distributed between the 3 treatment groups. In the subgroup of patients with a CD4 count <100 x 10(6)/l the survival was longer in the alternating arm (p <0.005) primarily because of differences among zidovudine naive patients. The alternating regime was better tolerated than the 2 monotherapies, with a longer time to dose reduction or withdrawal owing to side effects (p <0.001).
Original languageEnglish
JournalScandinavian Journal of Infectious Diseases
Volume29
Issue number2
Pages (from-to)121-8
Number of pages8
ISSN0036-5548
Publication statusPublished - 1997

    Research areas

  • Adult, Anti-HIV Agents, CD4 Lymphocyte Count, Didanosine, Drug Administration Schedule, Drug Therapy, Combination, Female, HIV Infections, Humans, Male, Middle Aged, Zidovudine

ID: 38982743